Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
|Eligible Ages||7 Years - 25 Years|
- - Moderate to severe peanut allergy-sensitive subjects between the ages of 7 to 25 years old.
- - Sensitivity to peanut allergen will be documented by a positive skin prick test result (6 mm diameter wheal or greater) - ImmunoCAP IgE level to peanut > 10 kU/L.
- - Sensitivity to peanut allergen based on a double-blind placebo-controlled oral food challenge (DBPCFC) at maximum of cumulative 175 mg of peanut protein dose.
- - Subjects with a total IgE at screening of < 50 kU/L > 2,000 kU/L.
- - Positive reaction to the placebo on DBPCFC.
- - Previous reaction to omalizumab.
- - Subjects having a history of severe anaphylaxis to peanut requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma, or gastrointestinal or gastroesophageal disease.
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
|Phase 1/Phase 2|
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
|Boston Children’s Hospital|
The person who is responsible for the scientific and technical direction of the entire clinical study.
|Lynda C Schneider, MDAndrew MacGinnitie, MD, PhDKari Nadeau, MD, PhDJonathan Spergel, MD, PhDJacqueline Pongracic, MD|
|Principal Investigator Affiliation||Boston Children’s HospitalChildren' Hospital BostonStanford UniversityChildren's Hospital of PhiladelphiaLurie Children's Hospital|
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
|Overall Status||Active, not recruiting|
The disease, disorder, syndrome, illness, or injury that is being studied.
|Peanut Allergy, Food Allergy|
36 subjects will receive Xolair, and 8 subjects will receive placebo. The study will occur at 4 sites: Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University and Lurie Children's Hospital. Patients will be pre-treated with Xolair or placebo before rapid oral peanut desensitization. Patients will continue to receive Xolair during the 8 subsequent weeks of desensitization, receiving their final dose of Xolair one week after reaching the highest tolerated dose of peanut.
Experimental: omalizumab group
Patients will receive omalizumab.
Placebo Comparator: placebo
Patients will receive placebo.
Drug: - Omalizumab
Drug: - placebo
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Stanford, California, 94305
Lurie Children's Hospital
Chicago, Illinois, 60611
Division of Immunology, Children's Hospital Boston
Boston, Massachusetts, 02115
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104